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South AfricaIntroduction: Antimicrobial resistance is one of the most severe health threats globally. Extended spec-
trum b-lactamases (ESBLs) are enzymes produced by a variety of gram-negative bacteria, which lead
to an increase in resistance to commonly used antibiotics and are associated with higher morbidity
and mortality.
Objectives: Assess the prescribing practices prior to, and after, positive ESBL producing microbiology cul-
tures in an adult ICU setting, according to sensitivity reports obtained from the clinical laboratories from
January 2013 until January 2014. Subsequently use the findings to guide future practice.
Method: Retrospective study at a private hospital in Pretoria, Gauteng Province. All adult patients older
than 18 years of age that were admitted to either the MICU (multi-intensive care unit) or the TICU
(trauma intensive care unit) with a positive producing ESBL culture during their hospitalised stay were
assessed.
Results: During the study period, 39 patients in the MICU and TICU had positive ESBL microbiology
results. The majority of positive ESBL results were due to Klebsiella pneumonia isolates. Antibiotics pre-
scribed post ESBL positive culture were appropriate according to the sensitivity report in 64% of patients.
22 patients survived and 17 patients died. All the patients that died were on invasive ventilatory support.
Conclusion: Clinically it appears as if patients who received appropriate therapy according to the micro-
biology results showed a better clinical outcome than those with inappropriate therapy. This underlines
the importance of appropriate prescribing practices in combination with co-morbid conditions. Invasive
ventilatory support can be identified as a clear risk for contracting an infection due to an ESBL producing
organism.
 2018 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction World Health Assembly in 2015 adopting a global action plan onAntimicrobial resistance (AMR) is one of the most severe health
threats, both globally and in South Africa.1 This is illustrated by theAMR, which underlines a global consensus that AMR poses a pro-
found threat.2 This is illustrated in South Africa and among sub-
Sahara African countries with efforts to document current antimi-
crobial utilization patterns, investigate antimicrobial stewardship
programmes and assess antimicrobial utilization against current
guidance.3–8 Infections from resistant bacteria are becoming more
common, and some pathogens have even become resistant to mul-
tiple classes of antibiotics. Extended-spectrum b-lactamase (ESBL)
producing bacteria have become recognized as a challenge in South
Africa with an extremely high prevalence of ESBL producing organ-
isms. The ESBL producing organism rate for Klebsiella pneumoniae
cultured from complicated intra-abdominal infections in private
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in the public sector varies between 55 and 74%.9
AMR occurs when bacteria change in a way that eliminates or
reduces the effectiveness of the drugs available to treat them.10
Our ability to treat infectious diseases, and to manage infectious
complications in vulnerable patients, is undermined by the loss
of effective antibiotics leading to increased morbidity, mortality
and costs.1,11
Extended spectrum b-lactamase (ESBLs) are enzymes produced
by a variety of gram-negative bacteria which leads to an increase
in resistance to commonly used antibiotics. Infections caused by
such enzyme-producing organisms are associated with higher
morbidity and mortality.2 The increasing prevalence rates of ESBL
producing organisms worldwide, coupled with the lack of devel-
opment of new antibiotics in the short term, symbolizes an appre-
ciable danger to public health.12 According to the latest data in the
United States, patients with bloodstream infections caused by
ESBL producing Enterobacteriaceae have a 57% higher mortality
than those with bloodstream infections caused by a non ESBL pro-
ducing strain.11
According to Coetzee and Brink, the utilisation of ertapenem,
meropenem and, imipenem in the private sector in South Africa
more than doubled between January 2009 and June 2011.13 Whilst
it is recognized that the carbapenems are the cornerstone of ther-
apy for patients with serious infections caused by ESBL producing
organisms, the high prevalence of ESBL amongst bacteraemic
pathogens places a tremendous strain on the use of these agents
both as empiric therapy as well as directed therapy. Not only does
the increasing consumption of the carbapenems create an ideal
environment for the development of carbapenem resistance among
the Enterobactericeae, carbapenem use has been shown to be a risk
factor for subsequent infections with ESBL producing organisms
through selective pressure. Inappropriate use is selecting for the
very resistance that the class is being used for.13 In the public health
care sector in South Africa, K. pneumoniae showed a higher rate of
resistance than E. coli bacteraemia,14 which is also a concern.
In view of these concerns, wewanted to investigate the situation
within the ICU of a leading large private hospital in South Africa to
improve the future care of these patients. This is because in the
beginning of 2013, a significant increase in the number of ESBL pro-
ducing isolates was noticed, with 18 patients producing ESBL posi-
tive cultures in one month. Consequently, this study aimed to
evaluate prescribing practices among patients in an intensive care
unit (ICU) setting prior to and post positive ESBL producing organ-
isms, according to the positive microbiology results. Subsequently,
use the findings to improve future prescribing if pertinent.2. Methods
2.1. Study design and population
This retrospective, quantitative study was performed at a pri-
vate hospital in Pretoria, Gauteng Province, South Africa, which is
the largest private hospital in South Africa with 470 beds. The
multi- and trauma ICU in this private hospital contains 29 beds,
with the multi-intensive care unit (MICU) and Trauma intensive
care unit (TICU) having 21 beds and eight beds respectively. The
ICU has an average of four patients per month with positive ESBL
producing organisms. The study followed an epidemiological
observational design.2.2. Data collection and analysis
Purposive sampling was used for all consecutive patient files of
adult patients older than 18 years that were admitted to these twounits that had cultured positive ESBL producing organisms during
their hospitalised stay from January 2013 until January 2014. Since
the study was a census, the data from all the files during the study
period were recorded on a form designed according to recommen-
dations by Gregory and Radovinsky.15 The data from the patient
files were collected, managed, and analysed using the IBM Statisti-
cal Package for Social Sciences Statistics (SPSS) programme.
Descriptive statistics were used to analyse data for prescribing pat-
terns in the presence of ESBL producing organism. This was fol-
lowed by determining the antibiotics that were prescribed prior
to the diagnosis of ESBL producing organism and after ESBL pro-
ducing organisms were diagnosed.
Antibiotic use would be considered appropriate when the
antibiotic prescribed was sensitive according to the microbiology
result obtained from the laboratory data. The total daily consump-
tion (TDC) refers to the antimicrobial dose that the patients
received, with this methodology used in studies to monitor antimi-
crobial utilization.15,16 Defined daily doses (DDD) were also calcu-
lated with DDDs being the assumed average maintenance dose per
day for a medicine used for its main indication in adults according
to the World Health Organisation (WHO).2,15,17,18
The Fischer exact test was used to test the association between
variables such as patients’ gender, age, diagnosed condition and
length of stay in the adult ICU and the antibiotic prescription pat-
terns. The Pearson correlation test was used to determine the sta-
tistical correlation between the combined age/co-morbid score and
the relative risk of death ratio according to the Age-Adjusted Charl-
son Comorbidity index (AACI).
2.3. Risk factors for infection due to ESBL producing organisms
Each patient was included as a case only once. If an ESBL pro-
ducing organism was isolated on multiple occasions, only the first
episode of infection was reviewed. Hospital acquired infections are
defined by the Centers of Disease Control (CDC) as an infection that
occurred >48 h after admission to the hospital, infection up to
3 days after discharge and/or infection up to 30 days after an
operation.19
The presence of a central venous catheter, urinary catheter, or
mechanical ventilation was also assessed. Finally, all antimicrobial
therapy that was administered prior- and post to positive ESBL
producing cultures were documented. The presence of the follow-
ing comorbid conditions was also documented: malignancy, dia-
betes mellitus, renal insufficiency, HIV infection and neutropenia.20
Several instruments have been developed to assess the extent of
co-morbidity and grade the degree of comorbid burdens using
ordinal scales. One of the most widely applied is the Charlson
Comorbidity Index (CCI), which has been extensively used to eval-
uate the impact of comorbidity in a variety of medical conditions.
The CCI was developed in 1987 and is a prognostic taxonomy that
was initially developed to account for the influence of a patients’
adverse medical conditions in longitudinal studies, and has been
validated in many clinical settings.21,22 This index is calculated
by the summation of weight scores for 19 medical conditions
and high scores were found to be associated with poorer
prognosis.21,22
Age has also been determined to be associated with overall sur-
vival, this was the CCI modified by Charlson et al. in 1994.23 This
modification called Age-Adjusted Charlson Comorbidity index
(AACI) includes the age of the patient as a correction variable of
the final score of the Charlson index. Peterson et al. reported that
each decade of age 50 years is equivalent to a 1-point increase
in comorbidity (i.e. 50–59 years = 1 point; 60–69 years = 2
points).24 The AACI was used to assess the patient’s estimated rel-
ative risk of death as only two patients in this study were younger
than 50 years of age. The ACCI score was calculated for these
Table 1
Baseline demographic and study characteristic information.
Data characteristics No (%) of Patients (IQR)
Demographic data
Total patients 39 (100%)
Male 29 (72%)
Female 11 (28%)
Age (years), median (IQR) 62.35 (24–92)
LOS in ICU (days) 22.15 (2–63)
Clinical data
Admission diagnosis n = 39
Intestinal obstruction 5 (13%)
Heart failure 1 (3%)
Malignant neoplasma 2 (5%)
Pulmonary problems 4 (10%)







Charlson score, median (IQR) 5 (3–8)
Community acquired infection (CAI) 3 (7.7%)
Hospital associated infection (HAI) 36 (92.3%)
Origin of the infection
Source of culture n = 39
Blood 6 (15%)
Lung tissue 1 (3%)
Sputum 22 (56%)
Duodenal swab 1 (3%)
Urine 9 (23%)
Microbiology data n = 39
Citrobacter koseri 1 (3%)
Escherichia coli 4 (10%)
Enterobacter cloacae 2 (5%)
Enterobacter aerogenes 1 (3%)
Klebsiella pneumoniae 31 (79%)
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by Yang et al., i.e. having either low comorbidity (CCI = 0–1), mild
comorbidity (CCI = 2–3), moderate comorbidity (CCI = 4–6) or sev-
ere comorbidity (CCI  6).25
2.4. Role of ESBL-resistance in outcomes
To evaluate the effect of infections due to ESBL producing organ-
isms on clinical outcomes, the following outcomes were assessed:
clinical outcome,mortality, duration of ICU stay and ventilation sta-
tus. The antimicrobial exposures before and after the positive ESBL
producing organisms were cultured were also assessed.
2.5. Microbiological methods
Clinical samples were processed according to standard microbi-
ological procedures. Bacterial isolates were identified with the Bru-
ker MALDI Biotyper. Antibiotic susceptibility testing was
performed using the Vitek 2 (bioMerieux, Johannesburg, South
Africa), and interpreted according to the criteria of the 2013 Clini-
cal and Laboratory Standards Institute (CLSI). K. pneumoniae and
E. coli isolates were suspected of ESBL-production if the MIC was
2 mg/mL for ceftazidime, cefotaxime or ceftriaxone.26 Such iso-
lates were subjected to a phenotypic confirmatory test, performed
by incubating the isolates with disks containing 30 mg of cefo-
taxime and ceftazidime, with and without clavulanic acid (10 mg;
Oxoid Ltd, Basingstoke, UK). The zone of inhibition was measured
after 16–18 h incubation, and an increase of 5-mm in a zone
diameter of either agent tested in combination with clavulanic acid
vs the zone of the diameter when tested alone was considered to
be positive for ESBL-production.
There are no CLSI criteria for confirmation of ESBL-production
in Enterobacter spp. ESBLs are more difficult to detect in those gen-
era that have inducible AmpC chromosomal enzymes, as these
enzymes can be induced by clavulanic acid, and then hydrolyse
the indicator cephalosporin. Cefepime is however a poor substrate
for AmpC b-lactamases. In Enterobacter spp with MICs of 2 mg/mL
for cefotaxime or ceftazidime, ESBL production was suspected. We
performed a double disk potentiation test between a cefepime
disk and an adjacent amoxicillin-clavulanate disk on these iso-
lates. This test is performed by placing a cefepime disk (30 mg)
15 mm (edge-to-edge) from a disk containing amoxicillin-
clavulanate (20 mg/10 mg).27
2.6. Ethical considerations
Ethical approval was obtained from the University of Limpopo –
Medunsa Campus (Number MREC/H/227/2014: PG) and from the
research operations committee of the private hospital were the
study was conducted – (Number UNIV-2014-0050).
Participant consent was not obtained for this study. This study
was considered as an epidemiological observation study. Partici-
pant personal information was only used to match the laboratory
report obtained from the laboratory dataset. Once this was done,
the patient’s personal data was anonymised and stored in a locked
cupboard.3. Results
3.1. Study population and socio-demographic characteristics
During the study period, 39 patients had positive ESBL produc-
ing isolates. Of these, more than 70% were male (Table 1). Respira-
tory distress was the initial admitting diagnosis for 41% of patients,
with the mean age of patients being 62 years, with only twopatients younger than 50 years. 36 patients received antibiotics
prior to the positive ESBL producing organisms being cultured
(92.3%) and the remaining three patients (7.7%) only received
antibiotics after the positive ESBL producing organisms were cul-
tured. Infections for 36 patients (92.3%) were classified as
hospital-acquired infections and three patients (7.7%) as commu-
nity acquired infection.
Table 1 provides an overview of the baseline characteristics for
the patients. Most patients were male (72%).
The sources where the positive cultures were principally from
sputum (56%), followed by urine (23%) and blood cultures (15%)
(Table 1). The majority of positive ESBL producing isolates were
due to Klebsiella pneumoniae isolates (79%).
3.2. Comorbidity index
38.5% of patients had severe ACCI scores (Table 2), followed by
moderate (25.6%) and mild (20.5%) (Table 2). Table 2 also cate-
gorises the relative risk of death ratio (RR) in relation to ACCI.
The clinical outcome of the sample population corresponds
with the prediction calculated by the AACI. According to the
Pearson Correlation, there is a statically significant correlation of
0.01 between the combined age/co-morbid score and the relative
risk of death ratio, which highlights the importance of co-morbid
conditions in critically ill patients.
3.3. Prescribing patterns
In this study, 91 different antimicrobials were prescribed for 39
patients prior to the positive ESBL producing organisms being
Table 2
Age adjusted Charlson comorbidity index and clinical outcome (n = 39).
Combined age/co-morbid score Amount N = 39 Percentage N = 39 Relative risk of death Clinical outcome
percentage (n = 39)
Survived Died
0–1 6 15.4% 0–1.45 100 0
2–3 8 20.5% 2.10–3.40 87.5 12.5
4–6 10 25.6% 4.40–9.23 70 30
>6 15 38.5% 9.23–19.37 13.3 86.7
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ferent antibiotics. The first antimicrobials that the patients
received were as follows: twenty one patients (54%) received other
b-lactam antibiotics as empiric therapy, seven patients (18%)
received fluoroquinolones, three (8%) patients received a car-
bapenem, with additional antimicrobials contained in Table 3.
Eight patients received one antimicrobial agent before positive
ESBL producing organisms were isolated, with the majority
receiving more (Table 4).
3.4. Appropriate use of antibiotic’s post positive ESBL producing
culture
The prescribing practices post positive ESBL producing organ-
isms being cultured are summarised in Table 5.
The majority (64%) of all antibiotics prescribed post positive
ESBL producing organisms were appropriate according to the sen-
sitivity report. Antibiotics were prescribed to nine patients (23%)
despite resistance to the said antibiotics on the culture reports.
One (3%) isolate was not treated as the patient passed away before
the antibiotic was started. There was no sensitivity results avail-
able for four (10%) of the antibiotics prescribed after the positive
culture.
3.5. Sensitivity and clinical outcome
Most (95%) of the ESBL producing organisms isolated in the 39
patients during the study period were sensitive to the carbapenem
antibiotics. One E. aerogenes sputum isolate was only sensitive to
imipenem, and one K. pneumonia blood isolate showed resistance
to imipenem.Table 3
Details of the first antimicrobials patients received.
Number of patients
(N = 39)
Antimicrobial received and ATC code Percentage
21 b-lactam (J01C, J01DB to DE) 53.8%
7 Fluoroquinolones (J01MA) 17.9%
3 Carbapenem (J01DH) 7.7%
2 Tetracyclines (tigecycline) J01AA 5.1%
1 Aminoglycosides (J01G) 2.6%
1 Imidazole derivatives (J01XD01)
(Metronidazole)
2.6%
1 Other bacterials J01XX (Linezolid) 2.6%
3 Others 5.7%
Table 4
Number of antibiotics patients received before positive ESBL organisms were isolated.






2 0Twenty two (56%) patients survived and 17 (44%) patients died.
It is clinically significant to note, however, that of the survivors,
32% (n = 7) received inappropriate antibiotics. Of the 17 patients
who died, eight (47%) received appropriate therapy, four (23%)
received inappropriate therapy, there were no sensitivity reported
for four (23%) isolates and one patient (6%) did not receive any
antibiotics because he passed away before antimicrobial therapy
could be started. The difference between those survivors who
received appropriate therapy versus those who did not was not
statistically significant (p = 0.209) (Table 6).4. Discussion
ESBL producing organisms were most frequent in patients aged
between 51 and 60 years, similar to the findings of Dey et al.28
The mean length of stay in the ICU in our study was 22.15 days
(range 2 to 63 days – Table 1), with ICU stay known to increase the
patients’ risk of contracting infections caused by ESBL producing
organisms.29 According to a study conducted by Kramer and Zim-
merman,30 there are distinct differences between patients with
an ICU stay <5 days versus those with an ICU stay 5 days. Patients
with an ICU stay 5 days had significantly higher severity of ill-
ness, frequency of mechanical ventilation, ICU readmission and
emergency surgery. Patients with an ICU stay 5 days accounted
for 21% of all admissions but 63% of total ICU days; and their out-
comes were uniformly poorer.30 In this study, 90% of patients were
in the ICU for longer than five days.
Of the 39 patients with ESBL producing organisms, 30 (77%) had
infections due to K. pneumoniae and four (10%) were due to E. coli.
Most isolates were cultured out of the respiratory tract (56%) fol-
lowed by the urinary tract (23%). The results seem to correspond
to global findings where K. pneumoniae and E. coli remain the dom-
inant ESBL producing organisms.31
In this study population, 36 patients (92%) were on invasive
ventilatory support and only three patients were on non-invasive
ventilatory support. This might also play an important role regard-
ing the acquisition of an ESBL producing infection with the
introduction of invasive devices. Twenty two patients survived
(56%) and 17 patients died (44%). All the patients that died were
on invasive ventilatory support. According to Kritsotakis et al.,
non-antibiotic risk factors for carbapenem sensitive ESBL produc-
ing K. pneumonia organisms included invasive ventilator support,
central vascular catheterization, urinary catheterization and
tracheostomy.32
The relatively high ACCI index, the ventilation status of the
patients, as well as the increased duration of stay in ICU in this
study population, confirmed the appreciable contribution to the
risks of patients contracting a positive ESBL producing organism
and the their outcomes similar to other studies.29 The importance
of comorbid conditions was underlined by the statistical significant
implication on the risk of death according to the ACCI correlation.
Having said this, the morbidity calculator does not take in account
respiratory distress or dependence on ventilatory support. Conse-
quently, additional care is needed when treating these patients.
Table 5
Prescribing practices after positive ESBL producing culture.
Cultures obtained (n = 39) Sensitivity yes/no/not
reported (NR)
Initial Prescribed therapy (frequency)
(and ATC code)
TDC (g) DDD Appropriate prescribing
yes/no/not reported (NR)
Blood (6)
K. pneumoniae (5) Yes Doripenem (2) (J01DH04) 3 1.5 Yes
Yes Ertapenem (1) (J01DH03) 1 1 Yes
Yes Meropenem (1) (J01DH02) 6 3 Yes
NR Piperacillin/Tazobactam (1) (J01RA01) 13.5 14 NR
E. cloacae (1) Yes Imipenem (1) (J01DH) 4 2 Yes
Sputum (22)
K. pneumoniae (18) Yes Cefepime (2) (J01DE01) 4 2 No
Yes Ceftriaxone (1) (J01DD04) 2 2 No
Yes Ciprofloxacin (1) (J01MA02) 0.8 0.5 No
Yes Doripenem (2) (J01DH04) 2.25 1.5 Yes
Yes Ertapenem (2) (J01DH03) 2 1 Yes
Yes Imipenem (4) (J01DH) 2.5 2 Yes
Yes Meropenem (4) (J01DH02) 4.5 3 Yes
Yes Moxifloxacin (1) (J01MA14) 0.4 0.4 No
NR Tigecycline (1) (J01AA12) 0.2 0.1 NR
No antibiotic received (1) No
C. Koseri (1) Yes Meropenem (1) (J01DH02) 3 3 Yes
E. aerogenes (1) Yes Amikacin (1) (J01GB06) 1 1 Yes
E. coli (1) Yes Cefepime (1) (J01DE01) 6 2 No
Duodenal swab (1)
K. pneumonia (1) Yes Doripenem (1) (J01DH04) 3 1.5 Yes
Lung tissue (1)
K. pneumonia (1) Yes Cefepime (1) (J01DE01) 3 2 NR
Urine (9)
Ent. cloacae (1) Yes Amoxicillin (1) (J01CA04) 2 1 No
E. coli (3) Yes Ciprofloxacin (1) (J01MA02) 0.8 0.5 No
Yes Doripenem (1) (J01DH04) 3 1.5 Yes
Yes Meropenem (1) (J01DH02) 4 3 Yes
K. pneumonia (5) Yes Cefepime (1) (J01DE01) 3 2 No
Yes Ertapenem (1) (J01DH03) 2 1 Yes
Yes Tigecycline (2) (J01AA12) 0.2 0.1 Yes
NR Vancomycin (1) (J01XA01) 2 2 NR
TDC = Total daily consumption; DDD = Defined daily dose; NR = not reported.
Table 6
Clinical outcomes for patients as compared to appropriate vs inappropriate therapy received.
Clinical outcome of patients











Survived (n = 22) – 56.4% 15 (68%) 7 (32%) – – p = 0.209
Deceased (n = 17) – 43.6% 8 (47%) 4 (23%) 4 (24%) 1 (6%)
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Numerous studies underline the impact of antimicrobial expo-
sure and the risk of developing an ESBL producing related infec-
tion.31,32 Antibiotic consumption, including the use of third
generation cephalosporins, other b-lactams and fluoroquinolones,
are also well-established risk factors shown to be associated with
the acquisition of ESBL producing organisms.32 This is similar to
our study where more than 70 percent (77%) of the patients
received other b-lactam antibiotics prior to positive ESBL produc-
ing organisms being cultured. These included cephalosporins,
piperacillin/tazobactam and penicillins, which might play a role
in enhancing an ESBL producing related infection.33 Other antimi-
crobial exposure includes fluoroquinolones (36%), carbapenems
(33%) and aminoglycosides (10%).
4.2. Prescribing practices after positive ESBL producing results and
clinical outcome
The majority (64%) of all antibiotics prescribed post positive
ESBL producing organisms were appropriate according to the sen-sitivity report. According to Pannell, the simple approach to sensi-
tivity analysis, given its ease and transparency, may even be the
optimal method for the purpose of practical decision making.34
Patients who receive appropriate therapy according to the
microbiology results showed a better clinical outcome than those
with inappropriate therapy; however, whilst these results were
not statistically significant they underline the importance of
appropriate prescribing practices after positive microbiology
results.
Just under half (47%) of the patients who died also received
appropriate treatment after positive ESBL producing organisms,
which underlines the fact that sensitivity and microbiology results
cannot be interpreted without taking the patients’ co-morbidity
into consideration. This was also confirmed in a study done by
Van Daalen et al.35
Overall, we believe our findings provide a stimulus to establish
an antimicrobial stewardship team (ASTs) in this hospital, and
likely in other hospitals in South Africa, to reduce inappropriate
prescribing and dispensing and reduce AMR rates.4 Coetzee and
Brink underlined the importance of an antibiotic stewardship team
and suggest that restrictive measures, even when perceived as
546 T. Fourie et al. / Alexandria Journal of Medicine 54 (2018) 541–547punitive measures, may be required to influence future antibiotic
prescriptions.13 Similar activities have been seen in other countries
to try and reduce AMR rates.36–40 The AST should provide advice to
improve and adapt antibiotic prescriptions, and to encourage pre-
scribers to adapt their treatment in accordance with local sensitiv-
ity reports and recommendations, with evidence-based prescribing
and dispensing seen as a future standard of care.2,41,42 Prescribing
practices can be positively influenced by pharmacists through rela-
tionship building with prescribers and by leading and driving
antibiotic stewardship initiatives building on the South African’s
government initiatives to reduce AMR rates.4,41 As part of this,
de-escalation should also be systematically proposed when clinical
and microbiological data allows for this using patient co-
morbidities to guide suggested therapies.5. Limitations
We are aware that the study followed a retrospective, epidemi-
ological observational approach, with some the patient files incom-
plete. In addition, the findings were based on the data captured by
the infection prevention practitioner of the hospital where the
study was conducted and we did not look at issues of mortality
broken down by de-escalation or no de-escalation. We are also
aware that we used the 27th edition of CLSI for our study analysis
and not the 28th edition, and that the study was conducted in only
one hospital in South Africa. However, this is a leading private hos-
pital in South Africa providing guidance to others. Consequently,
we believe that despite these limitations our findings are robust
providing direction for the future in this and other hospitals in
South Africa.6. Conclusion
The length of ICU stay, ventilatory status, and prior exposure to
antibiotics were found to be significant risk factors associated with
ESBL producing E. coli and/or K. pneumoniae acquisition status of
patients. Consequently, restricting the use of antibiotics, along
with implementation of infection control measures, should help
control and decrease the spread of ESBL producing pathogens.
Recommendations to this and other leading hospitals in South
Africa in light of our findings also include writing and implement-
ing an antibiotic policy in the MICU and TICU, as well as taking into
consideration the ventilatory status and co-morbid conditions of
patients to limit antimicrobial exposure. In this study, there was
no indication if the antibiotic was de-escaled to avoid carbapenem
use, and factors associated with omission of de-escalation should
be studied further especially if they have an influence on mortality
rates. There should also be a strong urge to establish proactive
ASTs to monitor these efforts.
There was also no indication if the infections were colonisa-
tions or an active infection, which is an important part of
antimicrobial stewardship. Consequently, it is recommended that
future studies of this nature be limited in scope to ensure
effective focus and in depth evaluations of specific guidelines
related to antibiotic prescriptions. We also believe it is important
that future researchers undertake a mix of quantitative and
qualitative study designs, which will allow in-depth research of
the prescribers’ views when prescribing antibiotics to better plan
for the future.
This hospital has now established a multidisciplinary AST, and
is working towards reducing irrational prescribing practices in
the ICU. Future research will concentrate on assessing the impact
of these initiatives including their influence on future clinical out-
comes and improved management of patients in the ICU.Conflict of interest
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